Passage Bio, Inc. (NASDAQ:PASG - Get Free Report) major shareholder Orbimed Advisors Llc sold 68,195 shares of Passage Bio stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $0.32, for a total value of $21,822.40. Following the transaction, the insider now owns 6,650,000 shares in the company, valued at $2,128,000. This trade represents a 1.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Tuesday, April 22nd, Orbimed Advisors Llc sold 78,049 shares of Passage Bio stock. The stock was sold at an average price of $0.34, for a total value of $26,536.66.
- On Thursday, April 17th, Orbimed Advisors Llc sold 77,090 shares of Passage Bio stock. The shares were sold at an average price of $0.33, for a total value of $25,439.70.
- On Tuesday, April 15th, Orbimed Advisors Llc sold 10,326 shares of Passage Bio stock. The stock was sold at an average price of $0.38, for a total transaction of $3,923.88.
Passage Bio Stock Down 3.3 %
NASDAQ PASG opened at $0.33 on Friday. Passage Bio, Inc. has a twelve month low of $0.30 and a twelve month high of $1.64. The business has a 50-day moving average price of $0.42 and a 200-day moving average price of $0.56. The firm has a market cap of $20.20 million, a price-to-earnings ratio of -0.28 and a beta of 1.59.
Passage Bio (NASDAQ:PASG - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. Research analysts expect that Passage Bio, Inc. will post -1.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Passage Bio
Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in Passage Bio by 18.2% in the 3rd quarter. Geode Capital Management LLC now owns 509,516 shares of the company's stock valued at $357,000 after acquiring an additional 78,406 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Passage Bio by 129.5% during the fourth quarter. Squarepoint Ops LLC now owns 64,099 shares of the company's stock valued at $36,000 after purchasing an additional 36,172 shares in the last quarter. Jane Street Group LLC grew its position in shares of Passage Bio by 537.2% during the fourth quarter. Jane Street Group LLC now owns 78,190 shares of the company's stock valued at $44,000 after purchasing an additional 65,919 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Passage Bio by 55.1% in the fourth quarter. Northern Trust Corp now owns 62,476 shares of the company's stock worth $35,000 after purchasing an additional 22,195 shares during the last quarter. Finally, Shay Capital LLC lifted its position in shares of Passage Bio by 144.2% in the fourth quarter. Shay Capital LLC now owns 225,261 shares of the company's stock worth $128,000 after buying an additional 133,005 shares in the last quarter. Institutional investors own 53.48% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital dropped their price target on shares of Passage Bio from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th.
Check Out Our Latest Stock Analysis on PASG
Passage Bio Company Profile
(
Get Free Report)
Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
